Netarsudil and latanoprost 0.02%/0.005% ophthalmic solution approved for use in EU for primary open-angle glaucoma or ocular hypertension

Approval of this combination treatment including netarsudil, a Rho-associated protein kinase inhibitor is specifically for use in adults with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil alone is insufficient.

Source:

Biospace Inc.